![Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)](https://www.pharmamirror.com/wp-content/uploads/2020/11/Gavreto_pralsetinib_100_mg_capsules-480x384.jpg)
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies,